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AspirinAbstract Non-steroidal anti-inﬂammatory drugs (NSAIDs) inhibit the growth of several cancer
cell lines. The aim of this study is to compare the cytotoxic effect of aspirin with diclofenac on
the growth of HeLa cell, mammary cell carcinoma, rhabdomyosarcoma and ﬁbroblast cell lines
in the culture media. The cells are cultured in RPMI-1640 culture media supplemented with 5%
fetal calf serum and antibiotics. Aspirin (5 mg/well) and diclofenac (0.625 mg/well) signiﬁcantly
inhibit the growth of HeLa, rhabdomyosarcoma and ﬁbroblast cells. The cytotoxic effect of aspirin
against rhabdomyosarcoma is signiﬁcantly (p< 0.001) higher than that of diclofenac with a
potency approximated 2.6. It concludes that aspirin and diclofenac inhibit the growth of ﬁbroblast
and cancer cell by inhibiting the up-regulation of cyclooxygenases enzymes in cancer cells. Aspirin is
more effective than diclofenac against the growth of rhabdomyosarcoma cell line.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Regular uses of non-steroidal anti-inﬂammatory drugs (NSA-
IDs) may reduce the risk of cancers of colon, breast, lung and
ovary (Cuzick et al., 2009; Rothwell et al., 2012; Wernli et al.,
2008).
Experimental studies demonstrated that diclofenac inhibits
the growth of tumor xenografts (Mayorek et al., 2010; Moody
et al., 2010) as well as the proliferation of cancer cell in a
concentration dependent manner (Smirnova et al., 2012).
Diclofenac inhibits the growth of melanoma cell by increasing
the cellular level of reactive oxygen species due to inhibition
484 M.S.M. Al-Nimer et al.the activity of superoxide dismutase enzyme in mitochondria
(Albano et al., 2013).
Aspirin induced apoptosis and inhibits the proliferation of
HeLa cells in a concentration dependent manner by a mecha-
nism related to the inhibition of the proto-oncogene (ErbB2)
downstream cell survival signaling pathways (Xiang et al.,
2010).
Aspirin interferes with the pathways of the proliferation
rhabdomyosarcoma cells by inhibiting the induction of the
matrix metalloproteinase enzyme activity (Ito et al., 2004).
Recently, Siddesha et al. (2014) demonstrated that aspirin
inhibits the migration of mouse cardiac ﬁbroblast by attenuat-
ing the level of interleukin-18, an interleukin involved in differ-
ent pathways that ultimately lead to reduce the migration of
ﬁbroblast and reducing ﬁbrosis. In one study, aspirin reduced
the breast cell line KM22 adhesion to human umbilical vein
endothelial cell while diclofenac failed to demonstrate that
effect (Bischofs et al., 2012).
The rational for doing this study is that aspirin or diclofe-
nac exerts a speciﬁc inhibitory action against the proliferation
of cells that links to its selectivity against cyclooxygenases
enzymes. This study aimed to compare the inhibitory effect
aspirin and diclofenac (non-selective cyclooxygenases enzyme
inhibitors) on the growth of three different cancer cell line
and ﬁbroblast.
2. Materials and methods
This study was conducted in the Department of Pharmacology
in the College of Medicine incorporation with National Center
of Cancer Research at Al-Mustansiriya University, Baghdad,
Iraq during 2014. The study was approved by the Institutional
Scientiﬁc Committee at the College of Medicine.Figure 1 Effect of aspirin on the growth of different cell lines.
The results are expressed as mean ± SD of each treatment
(n= 8), *p< 0.001.2.1. Cell Culture treatment and viability
HeLa, human rhabdomyosarcoma, mammary (AMN3) ade-
nocarcinoma and primary rat embryo ﬁbroblast cell lines (pro-
vided from The National Center of Cancer Research in
Baghdad, Iraq) were maintained in RPMI-1640 media with
5% fetal calf serum. All cultures were maintained in medium
supplemented with 0.5% ampicillin and 0.5% streptomycin
in 5% CO2 at 37 C. Several trials of cell reactivation are done
in order to obtain a monolayer cells in a speciﬁc falcon (vol-
ume 25 ml) which can be adjusted under the microscope to
look for the presence of monolayer cells. Once the growth of
monolayer cells has been formed, the old growth media dis-
carded, washed with phosphate buffer saline (PBS) buffer
once, add 0.5–1 ml Trypsin-versin solution, then add 10 ml
sterile growth media (supplemented with 5% fetal calf serum.
Then the dispersed cells transferred into a sterile microplate. A
total volume of 200 ll cells suspension is transferred into the
wells of the microplate, incubated at 37 C for 24 h to achieve
a monolayer cells growth. The cells were plated at 1 · 105 cells
per well in 200 ll of complete culture medium containing aspi-
rin (5 mg) or diclofenac (0.625 mg) and incubated at 37 C for
24 h. The concentration of aspirin that used in this study
amounted 8 times of that of diclofenac in attempt to mimic
the maximum tolerated therapeutic doses of these drugs.
The sterilization of the herbal tea achieved by mechanical
ﬁltration (using 0.2 lm millipore ﬁlter device) prior to theaddition. On the next day (i.e. after 24 h), the viability of cells
was determined by the MTT assay. A 30 ll of prepared
tetrazolium dye (3-[4,5-dimethylth-iazol-2-yl]-2,5-diphenyl
tetrazoliumbromide (5 mg/ml in phosphate buffer solution)
was added to each well in a dark room (to avoid oxidation
of the dye), and incubated for 2 h at 37.5 C in the incubator.
Then after, whole wells contents are discarded, 100 ll dimethyl
sulfoxide added, shake the microtitre plate for 15 min by using
horizontal shaker before recording the absorbance of each well
at 540 nm by ELISA reader.
2.2. Statistical analysis
The results are expressed as number, percent and whenever
possible as mean ± SD. The data are analyzed using Student’s
t test (unpaired, two tailed) and the difference between
percentages test taking the probability of 60.05 is the lowest
limit of signiﬁcance.
3. Results
Aspirin signiﬁcantly (p< 0.001) inhibits the growth of ﬁbro-
blast cell (53.7%± 6.3%) compared with un-treated cells
(100 ± 23%) (Fig. 1). A signiﬁcant (p< 0.001) inhibitory
effect of aspirin against the growth of HeLa cell line is
observed (17.0 ± 3.3%) compared with untreated cells
(100 ± 18.5%) (Fig. 1). A non- signiﬁcant (p> 0.05) cyto-
toxic effects of aspirin is observed (103.1 ± 28.7%) against
rhabdomyosarcoma cell line compared with un-treated cell line
(100.0 ± 18.5%) (Fig. 1). The growth of rhabdomyosarcoma
cell line is signiﬁcantly (p< 0.001) inhibited with aspirin
(26.1 ± 10.6%) compared with un-treated cell line
(100 ± 26.1%) (Fig. 1). As with aspirin, diclofenac has no sig-
niﬁcant effect against the growth of AMN3 mammary cell line
compared with un-treated cell line (118.5 ± 25.9% versus
100 ± 18.5%, respectively). The signiﬁcant effects of diclofe-
nac against ﬁbroblast, HeLa and rhabdomyosarcoma cell
lines are inferior to that observed with aspirin (Fig. 2). The
percents of ﬁbroblast, HeLa and rhabdomyosarcoma cell
lines growth decreased into 74.9 ± 10.8%, 21.2 ± 5.5% and
67.0 ± 25.3% respectively. The cytotoxic effect of aspirin
against rhabdomyosarcoma is signiﬁcantly (p< 0.001) higher
Figure 2 Effect of diclofenac on the growth of different cell lines.
The results are expressed as mean ± SD of each treatment
(n= 8), *p< 0.05, **p< 0.02, ***p< 0.001.
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(26.1 ± 10.6% versus 67.0 ± 25.3%).
4. Discussion
Aspirin and diclofenac signiﬁcantly inhibit the growth of
HeLa, rhabdomyosarcoma and the ﬁbroblast cell line. The
inhibitory effects of aspirin are higher than diclofenac sodium
that reached signiﬁcant against rhabdomyosarcoma. This
study shows that the inhibitory effect of aspirin on the growth
of HeLa cells is in agreement with other study that showed
aspirin potentiated the effect of the reversing (antitumor com-
pound) at a concentration of 10 mmol/L (Qin et al., 2013)
which is lower than the concentration of this study. Lee
et al. (2008) suggested that the anti-proliferative effect of
aspirin is due to the induction of the antitumor calpain via
activation the caspase-3. Wang et al. (2002) reported an inhibi-
tion of HeLa cell growth by diclofenac sodium in a concentra-
tion higher than that reported in this study. Therefore, the
cytotoxic effect of diclofenac may approximate the effect of
aspirin if equal-concentrations are used. The signiﬁcant differ-
ences between diclofenac and aspirin against the growth of
rhabdomyosarcoma may be related to the cyclooxgenase
expression as well as to the level of the matrix metalloprotein-
ase enzymes of the cells (Ito et al., 2004; Dickens and Cripe,
2003).
Reed et al. (2011) reported that celecoxib, a cyclooxygen-
ase-2 inhibitor, inhibits the formation of rhabdomyosarcoma
colonies, and they linked this effect to the different mecha-
nisms including inhibition of interleukin-6 induction and phos-
phorylation of STAT (Signal Transducer and Activator of
Transcription) protein signaling. The cytotoxic inhibitory
effects of aspirin and diclofenac are related to their effects
on cyclooxygenases enzymes 1 and 2 in which they show
up-regulation expression in ﬁbroblast (Abdou et al., 2014).
Recently, a new pharmaceutical formula termed closed packed
vesicle-diclofenac is developed. This pharmaceutical prepara-
tion can attack the ﬁbroblast cells and deposited in these cells
(Manca et al., 2013). Therefore, the difference between aspirin
and diclofenac against the ﬁbroblast cell growth may be
related to the concentration of the drug that deposited in ﬁbro-
blast cells. The results of NSAIDs on the mammary cell
growth do not agree the previous reports that showed aspirin
induced breast cancer apoptosis in presence of over-expressionof Bcl-2 gene (Choi et al., 2013; Hu et al., 2012). Therefore,
NSAIDs inhibit the growth of breast cell cancer in speciﬁc
experimental models, otherwise, their cytotoxic effect is
missed.
5. Conclusion
We conclude that aspirin and diclofenac inhibit the growth of
ﬁbroblast and cancer cell by inhibiting the up-regulation of
cyclooxygenases enzymes in cancer cells.
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